An observational study in Benign Prostate Obstruction (BPO), sponsored by University Hospital, Basel, Switzerland. Recruiting at 19 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by University Hospital, Basel, Switzerland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lower Urinary Tract Symptoms with a site in Germany — 3 open to participants now, 4 under way, none of them phase 3. Lower Urinary Tract Symptoms · Germany.
Among the 12 studies in Lower Urinary Tract Symptoms with a site in Germany, this one is the only one that started in 2022, is one of 4 observational ones, and was the 10th registered.
419 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.
Browse Lower Urinary Tract Symptoms studies →3 of the 12 studies in Lower Urinary Tract Symptoms with a site in Germany are open now. Recruiting first, the newest first:
University of Zurich · Sites in Germany, Switzerland
Ages 18+ · Men only
Ludwig-Maximilians - University of Munich · Sites in Germany
Ages 18–100
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 60 Lower Urinary Tract Symptoms studies recruiting now, 40 (67%) set no upper age limit and 11 (18%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 150 across 133 observational studies indexed under Lower Urinary Tract Symptoms.
Median enrollment 817 across the 8 interventional studies, 128 across the 4 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 10 most frequent:
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
University Hospital, Basel, Switzerland has 1 study filed under Lower Urinary Tract Symptoms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Lower Urinary Tract Symptoms with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to assess the clinical data of Rezum (water vapor therapy) in patients with BPO (benign prostate obstruction) and male LUTS (lower urinary tract symptoms) in terms of efficacy, durability and safety in a large, prospective, multi-center cohort consisting of 1000 "real-life" patients with a follow-up of 5 years.
Prostate water vapor therapy (Rezum) is an approved treatment procedure for the management of lower urinary tract symptoms in men caused by benign prostatic obstruction (BPO). Rezum is performed transurethrally by steam injections into the central or transition zone of the enlarged prostate. The 103°C hot steam is generated by a generator and injected into the prostate tissue via a disposable handpiece with a retractable needle. Approximately 1 injection is required per 10 ml of prostate tissue to achieve desobstruction. The single injection takes only 9 seconds. The thermal energy contained in the water vapor is able to develop evenly and freely in the intercellular space of the prostate by convection. This represents a unique technique in surgical desobstruction of the prostate. The steam condenses and releases the stored heat energy to the cell membranes, which then denature. As a result, the prostate tissue shrinks by about 30% in the first three months after the Rezum treatment. The shrinkage process therefore does not take place immediately, but with a time delay. The minimally invasive nature of the procedure results from the short surgical time, the potential of Rezum to preserve sexual function (both ejaculation and erection), and the possibility of performing Rezum even under local anesthesia or analgesia. Data on efficacy, durability of efficacy, safety/complications, and indication groups are still limited. "Real life" data are important to determine the role of Rezum water vapor therapy in the treatment of BPO and male LUTS. The aim of this study is to prospectively enroll and follow Rezum patients in a multicenter, German-language, web-based database. Patient-reported outcome measures (PROMs) and clinical-reported outcome measures/data (CROMs) on various subgroups of patients treated with Rezum as a routine clinical treatment option for BPO-related male LUTS will be recorded in terms of procedure efficacy, functional outcomes (e.g. sexual function) and surgical safety. Further aspects of interest are recovery from the procedure, patients' expectations towards Rezum treatment, patients' satisfaction with Rezum treatment, and impact of Rezum on quality of life.
Patients who are treated with Rezum - water vapor therapy of the prostate due to benign prostate obstruction (BPO) or male lower urinary tract symptoms (LUTS) as part of routine clinical practice. Patients will be recruited within the participating study hospitals as part of regular patient care after an indication for Rezum treatment has been made independent of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(*) also the combination with a planned transurethral procedure is not allowed except for bladder stone removal
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study uses a web-based German-language database (electronic data capture system, EDCS) called "REDCap" that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (initially iUFlow, since October 2025 EmanoFlow ) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy.
If patients have a smartphone with app function (Android or Apple), they will be provided with an FDA-registered home uroflowmetry mobile App (called EmanoFlow from Emano Metrics, USA) at study entry. This AI-based mobile application should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation. EmanoFlow is marketed by Emano Metrics Inc., a Delaware C Corporation with its principal place of business at 132 East Broadway Suite 700, Eugene, OR, 97401, USA. Every time a patient is using the mobile App urine flow measurement data will be sent to the home uroflowmetry database (Emano Flow Clinic Portal).
Change in International Prostate Symptom Score/ Quality of Life (IPSS/ QoL)
The IPSS is an eight-item validated questionnaire, consisting of seven symptom questions and one QoL question. The IPSS score is categorised as 'asymptomatic' (0 points), 'mildly symptomatic' (1-7 points), 'moderately symptomatic' (8-19 points), and 'severely symptomatic' (20-35 points).
Time frame: At baseline, 6 weeks, 3 months, 6 months, 12 months and annually until the 5th follow-up year after treatment with Rezum
Change of maximum urinary flow rate (Qmax) measured by uroflowmetry
Self-measured by patients at home using the iUFlow device (Kesem Health)
Time frame: At baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months and annually until the 5th follow-up year after treatment with Rezum
Change of International Consultation on Incontinence Questionnaire for male lower urinary tract symptoms (ICIQ-MLUTS)
The ICIQ-MLUTS is a widely used and validated patient-completed questionnaire including incontinence questions and bother for each symptom. It contains thirteen items (including incontinence questions and bother for each symptom), with subscales for nocturia and overactive bladder (OAB).
Time frame: At baseline, 6 weeks, 3 months, 6 months, 12 months and annually until the 5th follow-up year after treatment with Rezum
Change of Male Sexual Health Questionnaire (MSHQ)
The MSHQ long form includes 3 domains: Erection scale (3 items), Ejaculation scale (7 items), Sexual satisfaction scale (6 items) (additional 2 items measuring bothersome linked to erection and ejaculation). Additional Items (Sexual Activity and Desire) are not to be collected.
Time frame: At baseline, 6 weeks, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum
Change of International Consultation on Incontinence Questionnaire Male Sexual Matters Associated with Lower Urinary Tract Symptoms Module (ICIQ-MLUTSsex)
The ICIQ-MLUTSsex is a patient-completed questionnaire for detailed evaluation of male sexual matters associated with their lower urinary tract symptoms and impact on quality of life (QoL). It is composed of 4 sections (erection, ejaculation, pain/discomfort during ejaculation, impact of urinary symptoms).
Time frame: At baseline, 6 weeks, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum
Patient's postoperative recovery by QoR-15
Investigation of type of anesthesia (general anesthesia, spinal anesthesia, local anesthesia, analgosedation) incl. reason for type of anesthesia and postoperative recovery using the validated German version of the Quality-of-Recovery-Score (QoR-15GE).
Time frame: At baseline, at the first postoperative day and 2 weeks after treatment with Rezum
Change in PROMIS Global Health 10 questionnaire
Changes in Quality of Life associated with Rezum treatment using the PROMIS Global Health 10 questionnaire. It is a measure of overall health-related quality of life. The questionnaire consists of a combination of 10 questions that assess both the physical and mental health status of adult patients independent of their individual medical situation. The items are measured using a five-point response matrix that includes physical function, fatigue, pain, emotional distress and social health.
Time frame: At baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum
Change in ICIQ-S (International Consultation on Incontinence - Satisfaction)
The ICIQ-S (International Consultation on Incontinence - Satisfaction) will be used to evaluate patient satisfaction after urological surgery. Question items consist of: outcome success, comparison of symptoms, return to "normal life", same situation, same choice, recommend, current symptoms, preparation for surgery, satisfaction of explanation, pain after surgery, satisfaction of pain relief, current pain, complications/side effects, result of surgery and satisfaction with surgery.
Time frame: At 2 weeks, 6 weeks, 3 months, 6 months, 12 months and annually after treatment with Rezum
Numeric pain Rating Scale (NRS)
Investigation of patients' perception of pain during Rezum procedure in case of local anesthesia and/or analgosedation and after Rezum treatment using NRS. The NRS has the following scale: from 0 - 10 (no pain - worst pain imaginable).
Time frame: At the first postoperative day
Rezum side effects and Pain medication
This questionnaire is self-designed. Typical side effects must be seen and investigated independently of treatment complications in order to provide patients with the best possible advice and information. The need for pain medication will be evaluated in a time context as well.
Time frame: At baseline, 2 weeks, 6 weeks and 3 months
Patients' preferences and expectations of Rezum Treatment
This self-designed questionnaire considers measurement tools related to BPO/male LUTS treatment and aims to investigate patients' motivations, expectations and preferences for surgical desobstruction of the prostate due to BPO in general but also in particular concerning the Rezum treatment. This will attempt to better understand patient attitudes in order to improve future counseling of patients regarding minimally invasive procedures for the treatment of BPO-related male LUTS.
Time frame: At baseline, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum
Questionnaire: BPO (BPH)/LUTS medication
This self-designed questionnaire aims to evaluate the need for BPO (BPH)/LUTS medication.
Time frame: At 2 weeks, 6 weeks, 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum
Questionnaire: Reoperation
This self-designed questionnaire aims to evaluate the need for urological reoperation.
Time frame: At 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum
Questionnaire: Bladder catheter
This self-designed questionnaire aims to evaluate the need for bladder catheterization.
Time frame: At 3 months, 6 months, 12 months and then annually until the 5th follow-up year after treatment with Rezum
Number of steam injections and injection points during Rezum treatment
Investigation of the influence of the number of steam injections and Injection points on outcome parameters, micturition parameters, sexual function, prostate size, side effects and complications.
Time frame: At Baseline (on day of treatment with Rezum)
Retreatment rate
Number of retreatments (medical (drugs), bladder catheter and surgical) after Rezum treatment.
Time frame: Up to 5 years after treatment with Rezum
Surgical safety by classification of intraoperative adverse events (ClassIntra®)
The classification defines intraoperative adverse events as any surgery or anesthesia-related deviation from the ideal intraoperative course occurring between begin of anesthesia and end of anesthesia. Surgical safety is investigated by analyzing intraoperative complications classified by ClassIntra (from Grade 0: No deviation from the ideal intraoperative course to Grade 5: Any deviation from the ideal intraoperative course with intraoperative death of the patient).
Time frame: On day of treatment with Rezum
30-days postoperative complications by the Clavien-Dindo classification
The classification defines postoperative adverse events occurring after the patient has left the recovery room until 30 days after surgery (from Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological intervention to Grade V: Death of a patient).
Time frame: Within 30-days after treatment with Rezum
Antimicrobial prophylaxis
Investigation of the effectiveness of the chosen antimicrobial prophylaxis by analyzing the rate of postoperative symptomatic urinary tract infections (UTI) within the first 30 days after surgery as part of the Clavien-Dindo classification. Definition of symptomatic UTI is based on clinical diagnosis supported by measured bacteriuria of ≥105 cfu/ml treated with antimicrobial agents.
Time frame: Within the first 30 days after treatment with Rezum
Post voiding residual volume (PVR) measured by ultrasound
Change of post voiding residual volume (PVR) measured by ultrasound is a simple test that can raise or lower the suspicion of bladder outlet obstruction (BOO).
Time frame: Baseline and up to 5 years after treatment with Rezum
Change of prostate size
Measured by ultrasound or magnetic resonance imaging (MRI).
Time frame: Baseline and up to 5 years after treatment with Rezum
Change in bladder outlet obstruction index (BOOI)
BOOI is represented by the equation: BOOI = Pdet @ Qmax - 2 x Qmax (Pdet = detrusor pressure; Qmax = maximum flow rate). BOOI \> 40 = obstructed; BOOI 20-40 = equivocal; and BOOI \< 20 = unobstructed.
Time frame: Max. 6 months before Rezum and/or 3-6 months after Rezum treatment
Change in bladder contractility index (BCI)
The BCI is represented by the following formula: BCI = Pdet @ Qmax + 5 x Qmax. Using this formula, contractility can be divided into strong \> 150, normal 100-150, and weak \< 100.
Time frame: Max. 6 months before Rezum and/or 3-6 months after Rezum treatment
Change in International Prostate Symptom Score (IPSS) for detrusor (bladder muscle) overactivity (DO)
Urodynamic analysis of detrusor overactivity (DO) during storage phase and correlation of pre- and postoperative DO with PROMs (IPSS). The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.
Time frame: Max. 6 months before Rezum and/or 3-6 months after Rezum treatment
MRI (magnetic resonance imaging) data
MRI data not older than 12 months at time of Rezum treatment and MRI data in the follow-up period of 5 years are investigated in terms of prostate size, ablative lesions (lesions caused by Rezum) and PI-RADS (prostate imaging-reporting and data system) lesions.
Time frame: Max. 12 months before Rezum and up to 5 years after treatment with Rezum
Prostate cancer (PCa) detected by positive prostate biopsy
The proportion of patients who receive Rezum treatment with a history of prostate cancer or who develop histologically confirmed prostate cancer during the post-treatment course.
Time frame: Max 12 months and up to 5 years after treatment with Rezum
Doctors' preferences, motivations and reasons to use Rezum
Investigation of doctors' reasons for preference/choice of using Rezum in a patient using a self-designed questionnaire.
Time frame: Before treatment with Rezum
Change in ICIQ-Lower Urinary Tract Symptoms Quality of Life (ICIQ-MLUTS) score for detrusor (bladder muscle) overactivity (DO)
Urodynamic analysis of detrusor overactivity (DO) during storage phase and correlation of pre- and postoperative DO with PROMs (ICIQ-MLUTS). The ICIQ-MLUTS is a questionnaire for evaluating male lower urinary tract symptoms and impact on quality of life (QoL). 1-84 overall score with greater values indicating increased symptom severity.
Time frame: Max. 6 months before Rezum and/or 3-6 months after Rezum treatment
Not enrolling at this site.
PDFs hosted by the registry, ClinicalTrials.gov.
Started Dec 2022 (actual). Primary completion is estimated for Dec 2031, 108 months after the start.
Of 57 non-industry observational studies under Lower Urinary Tract Symptoms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 70. This study's planned 108 months is above that.
Counting every sponsor, half of 63 studies reached it within 33 months; a quarter within 11 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lower Urinary Tract Symptoms →
University Hospital, Basel, Switzerland →